Immunoglobulins regulate the complement system by activating complement on foreign surfaces and diverting reactive complement proteins away from autologous cell surfaces. Based on this model, we explored the ability of Ig to balance complement activation versus control in a pig-toprimate cardiac xenotransplantation model in which the binding of xenoreactive antibodies of the recipient to graft blood vessels and the activation of complement cause hyperacute rejection. Human IgG added to human serum caused a dose-dependent decrease in deposition of iC3b, cytotoxicity, and heparan sulfate release when the serum was incubated with porcine endothelial cells. This decrease was not caused by alteration in antibody binding or consumption of complement but presumably reflected decreased formation of C3 convertase on the endothelial cells. Infusion of purified human IgG into nonhuman primates prevented hyperacute rejection of porcine hearts transplanted into the primates. As expected, the transplants contained deposits of recipient Ig and Clq but not other complement components. The inhibition of complement on endothelial cell surfaces and in the xenotransplantation model supports the idea that IgG regulates the classical complement pathway and supports therapeutic use of that agent in humoral-mediated disease. (J. Clin. Invest. 1995Invest. .96:2404Invest. -2412
Introduction
IgG regulates the functions of complement through a number mechanisms. After specific binding to target antigens, IgG interacts with Clq to initiate the classical complement pathway (1, 2) . IgG activates the alternative complement pathway in part by generating C3b through classical pathway activation and in part by masking cell surface polyanionic sites which otherwise would promote interaction of factor H with C3b (3, 4) . IgG also serves as a ligand for covalent attachment of C3b, protecting C3b from inhibition by factor H (5, 6), promoting alter-native pathway function. In contrast to these properties, IgG may inhibit the action of complement on potential targets. This is in part accomplished by competing with target cells for binding of C3b, and possibly C4b, diverting C3 convertase(s) from antibody-coated target cells (7) . For example, we have shown that injection of large amounts of purified Ig prevents complement-mediated vascular collapse and death caused by administration of antibodies against the Forssman antigen in guinea pigs (7, 8) .
To understand better the balance between the effector and regulatory functions of IgG, we evaluated the extent to which IgG could modify hyperacute xenograft rejection, a well-characterized immune reaction, in which the binding to a graft of xenoreactive natural antibodies (9-12) triggers activation of complement through the classical pathway (11, 13) leading to endothelial injury and destruction of the organ graft in minutes to a few hours (14) (15) (16) (17) (18) . Approximately 1% of human IgG is thought to consist of natural antibodies directed against Gala ( 1-3 ) Gal ( 19, 20) , an epitope expressed by nonprimates (21 ) . Binding of xenoreactive IgM to this structure accounts for up to 80% of the binding of IgM to porcine endothelial cells and a corresponding fraction of complement activation (22) (23) (24) . Binding of IgG to this structure is also postulated to contribute to xenograft rejection (25) , although the mechanism is uncertain. The administration of human IgG containing these antibodies might thus amplify the immune reaction responsible for rejection of a xenograft or it might lessen or prevent the reaction.
Here we report that while human IgG administered to nonhuman primates does bind to a porcine organ, antibody binding does not lead to an appreciable increase in complement activation on graft blood vessels nor does it alter binding of xenoreactive IgM. Rather, the administration of IgG inhibits deposition of complement via the classical complement pathway on endothelial cells, in most cases preventing complement-mediated hyperacute rejection.
Methods
Human IgG. Gamimune® N (5% and 10%; Miles Laboratories Inc., Elkhart, IN) which was used in most experiments, consists of 98% IgG (manufacturer's insert). The vehicle for 5% Gamimune® N is 9-11% maltose, the vehicle for 10% Gamimune® N is 0.16-0.24 M glycine. Also evaluated were Gammagard® (Baxter Healthcare Corp., Glendale, CA), Gammar®-IV (Armour Pharmaceutical Co., Kankakee, IL), and Venoglobulin®-S (Alpha Therapeutic Corp., Los Angeles, CA), which contain predominantly IgG and only trace amounts of IgM and IgA. We therefore refer to the preparations as IgG.
To control for potential effects of the carrier, the IgG preparations were dialyzed against PBS in some experiments. The IgG preparations tions were centrifuged at 100,000 g for 30 min to remove Ig aggregates, and the concentration was determined spectrophotometrically. BSA (Fraction V; Sigma Chemical Co., St. Louis, MO) dissolved in PBS at a concentration of 50 mg/ml and filtered through a 0.22-,jm filter was used as a control. Immediately before use in vitro, the BSA was centrifuged at 100,000 g for 30 min and diluted to the desired concentration.
Human serum. Samples of serum were obtained from healthy human volunteers and stored at -70'C. Levels of IgG and IgM were determined by nephelometry. The level of xenoreactive natural antibodies was determined as described below. Serum from a donor with extremely low levels of xenoreactive antibodies was used as a source of human complement (15, 26) . Incubation of this serum (25% vol/vol) with porcine aortic endothelial cells for 60 min does not lead to deposition of iC3b as ascertained by ELISA. Endothelial cell cultures. Porcine aortic endothelial cells were explanted and cultured according to the method of Ryan and Maxwell (27) . Cultured in DME containing 10% FCS, 4 Endothelial cell cytotoxicity. Cytotoxicity was determined using a standard 51Cr release assay ( 14) . Porcine aortic endothelial cells grown to confluence on 24-well plates were labeled with 2 ttCi of Na5"CrO4 (New England Nuclear, Boston, MA) per well for 18 h. The cells were then treated for 4 h using the experimental or control conditions as indicated. The percentage of cytotoxicity was calculated using the following formula: % cytotoxicity = [(A -C)/(A + B -C)] X 100 where A equals radioactivity in the supernatant, B equals total radioactivity (extracted with 1.0 N NaOH), and C equals radioactivity in supernatant of cells treated with heat-inactivated serum.
Heparan sulfate release from endothelial cells. The effects of complement on the metabolism of endothelial cell-associated heparan sulfate proteoglycan was determined as described previously ( 14) . Glycosaminoglycans in endothelial cells cultured as described above were biosynthetically labeled for 16-20 h in sulfate-free medium containing 1% FBS and 0.1 mCi/ml [35S]NaSO4 (14, 30) . In this system, 96% of the labeled proteoglycans are heparan sulfate based on sensitivity to deaminative cleavage with nitrous acid.
The monolayers were incubated with 25% human serum with 0-20 mg/ml of IgG for 2 h and controls with 25% heat-inactivated serum. The supernatant and cell layers were extracted and dialyzed as previously described (14) , and the radioactivity of each fraction was determined by liquid scintillation counting. The percent heparan sulfate release was calculated as follows: [(cpm medium)/(cpm medium + cpm cells)] x 100.
Animals. Outbred, 6-12-kg pigs were used as cardiac xenograft donors (Walnut Hill Farm, Hillsborough, NC, and DNX Inc., Princeton, NJ). Male cynomolgus monkeys (Maccaca fascicularis, Crab-eating Macaques), [8] [9] [10] [11] [12] kg in size and female baboons (Papio species), 14-16 kg, were used as cardiac xenograft recipients.
Harvesting of porcine organs. Pigs were sedated with ketamine hydrochloride and anesthetized with isoflurane, and the kidneys and heart harvested as described previously (31) . A cannula was placed in the infrarenal aorta and the suprarenal aorta and vena were then ligated and the kidneys perfused with University of Wisconsin solution (Viaspan; DuPont-Merck Pharmaceutical Co., Wilmington, DE) at 40C.
For harvesting of the heart, the superior and inferior vena cava were ligated, the aorta cross-clamped, and the heart brought into arrest by perfusion with cardioplegia solution (Plegisol; Abbott Laboratories Diagnostic Div. Chicago, IL) at 4°C. The inferior vena cava and right inferior pulmonary vein were incised to vent the heart while saline slush was applied to provide topical cooling.
Porcine to primate cardiac xenografts. Porcine hearts were transplanted into cynomolgus monkeys as previously described (32) . On the day before transplantation, human Ig 2 g/kg was administered to the monkeys through a dual lumen Hickman catheter (Bard Access Systems, Salt Lake City, UT) placed in the right internal jugular vein. On the day of transplantation, a splenectomy was performed. The donor aorta was anastomosed end to side to the recipient abdominal aorta and the donor pulmonary artery was anastomosed to the inferior vena cava. This created a vascularized, beating, nonworking heart model. Upon Cardiac xenografts were performed in baboons as previously described (33) . In baboon recipients, the preoperative human IgG dose was 3 g/kg. On the day of transplantation, a splenectomy was performed. Anastomosis of the donor aorta to the carotid artery and donor pulmonary artery to the internal jugular vein were performed as previously described (34) (35) (36) . Postoperative immunosuppression and biopsy was the same as described for cynomolgus recipients. Graft function was monitored by inspecting the neck for cardiac contraction. In an effort to further extend xenograft survival, the blood of one baboon was perfused through two porcine kidneys as previously described (37) .
Histology and immunopathology. Biopsies of the porcine kidneys and hearts were prepared for light and immunofluorescence microscopy as previously described (11) . Samples of each biopsy fixed in 10% formalin were embedded, sectioned, and stained with hematoxylin and eosin. Samples for immunofluorescence studies were snap frozen in precooled isopentane and stored at -80'C until used. Frozen tissue sections (4 plm thick) were prepared in a cryostat (Leica Inc., Heidelberg, Germany), air-dried, fixed with acetone, and washed with PBS (38) . Tissue sections were incubated with an FITC-conjugated primary reagent or with unlabeled murine mAbs. Unlabeled mAbs were detected by application of a double fluorochrome layer consisting of affinityisolated FITC F(ab')2 goat anti-mouse IgG followed by affinity-isolated FITC F(ab')2 rabbit anti-goat IgG, both of which were absorbed with human and porcine serum before use. Tissue sections were washed with PBS after application of each reagent and mounted with p-phenylenediamine/glycerol solution (39) . Background immunofluorescence was assessed by omitting the primary antibody.
Determination of Ig and complement levels. Total serum IgG and IgM was determined by nephelometry, using reagents for human Ig. Plasma C4 levels were determined by functional titration. Properdin and factor B levels were measured by radial immunodiffusion (Kent Laboratories, Redmond, WA).
Results
Xenoreactive antibodies in human gamma globulin. The amount of xenoreactive natural antibodies in the human IgG preparations was measured by ELISA. As Fig. 1 shows, commercial preparations contained xenoreactive IgG, the binding of which reached saturation at concentrations above 2.5 mg/ ml. There was no significant lot-to-lot variability in the level of xenoreactive IgG (not shown). The human IgG preparations contained < 0.4% IgM, very little of which bound to cultured endothelial cells.
Complement activation by Ig. The ability of the xenoreactive antibodies in the IgG preparations to activate complement was investigated by incubating porcine endothelial cells with IgG and then with human complement and measuring the amount of iC3b neoantigen deposited on the endothelial cell surface. As shown in Fig. 1 B, (7, 8) , IgG might also hinder the binding of xenoreactive antibodies through idiotype-antiidiotype interactions (40, 41) or through blocking. As Fig. 2 shows, addition of human IgG at various concentrations to human serum did not alter binding of the IgM in that serum to porcine endothelial cells but it did significantly decrease deposition of C4 and iC3b in a dosedependent manner.
Effect of IgG on complement-mediated cytotoxicity and heparan sulfate release. The ability of IgG to inhibit complementmediated injury was explored in a model in which complement activation depends on the classical pathway (13, 14) . Endothelial cell monolayers were incubated for 4 h with 25% human serum containing varying amounts of human IgG, and specific cytotoxicity was then determined. The addition of IgG to human serum decreased cytotoxicity in a dose-dependent manner by up to 86.9±5.0% (Fig. 3) . Similar results were achieved using four different commercial preparations of gamma globulin (not shown). The protective property of IgG was eliminated by heating the immunoglobulin solution to 100°C for 15 min followed by centrifugation (not shown). The protective effect of IgG was not dependent on unique characteristics of the human serum used, as similar results were observed using four different human sera (not shown). The effects of IgG were not a nonspecific effect of the added protein, since addition of BSA to serum had no effect (Fig. 4) . Nor was the protective effect due to the carrier solution, since dialyzing the Ig preparation against PBS actually increased protection against complement-mediated cytotoxicity. Immunoglobulln (mg/ml) Figure 3 . Purified human IgG inhibits complement-mediated cytotoxicity. Porcine aortic endothelial cells were incubated with 25% human serum to which varying amounts of purified human IgG was added. Cytotoxicity was measured using a 51Cr release assay as described in Methods. Results are expressed as the mean of triplicate wells ±SEM, and are representative of six experiments. Figure 4 . Effect of proteins on cytoprotection mediated by purified human IgG. Porcine aortic endothelial cells were incubated with 25% human serum for 4 h in the presence of PBS alone, 10 mg/ml BSA diluted in PBS, or Gamimune® N at 10 mg/ml which was either first dialyzed against PBS or diluted from the stock preparation. The results are expressed as the mean of triplicate wells ±SEM.
As a measure of noncytotoxic, complement-dependent injury to endothelial cells, the effect of IgG on complementmediated release of heparan sulfate from endothelial cells was evaluated (14) . Addition of IgG to human serum decreased heparan sulfate release from porcine endothelial cells in a dosedependent manner by up to 93.2+2.5% (not shown).
Prevention of hyperacute rejection in porcine-to-primate cardiac xenografts by IgG. To test whether human IgG would prolong survival of vascularized xenografts, four porcine-tocynomolgus monkey and two porcine-to-baboon cardiac xenografts were performed with administration of IgG in the pretransplant and postoperative period. The results of these experiments are summarized in Table I . In two cynomolgus monkey recipients, hyperacute rejection was prevented; one heart functioned for 8 d (cyno 1), the other for 18 h when the monkey died suddenly (cyno 3). Two xenografts into cynomolgus recipients did not function and appeared to have been rejected hyperacutely (cyno 2 and cyno 4).
One pig-to-baboon xenograft survived 10.25 d (baboon 1). In an attempt to further extend xenograft survival, xenoreactive antibodies were depleted by perfusing the blood of a second baboon (baboon 2) through two pig kidneys and then IgG was administered. A porcine cardiac xenograft in this baboon survived 7.5 d. Analysis of the titers of xenoreactive natural antibodies however revealed that the kidney perfusions had not fully depleted xenoreactive IgM, the level of which was comparable to that of baboon 1 (not shown). In baboon 2, there was no significant change in C4, properdin, or factor B levels after the perfusions.
Histology and immunopathology ofcardiac xenografts. The histology of cardiac xenografts protected by purified IgG from hyperacute rejection revealed a few focal hemorrhages but none of the extensive tissue damage, hemorrhage, and thrombosis characteristic of hyperacute rejection. Biopsies on subsequent days revealed vascular lesions and thrombosis typical of acute vascular xenograft rejection, a condition observed when xenograft survival is prolonged by depletion of complement (42) .
Immunopathology of xenografts in the animals treated with
Immunoglobulin Prevents Complement-mediated Rejection IgG demonstrated diffuse staining for IgM and Clq along the endothelium of both large and small blood vessels (Fig. 5) .
IgG was also present along the endothelium and in extravascular compartments (not shown). Despite the deposition of IgM, IgG, and Clq, the tissues from hearts in which hyperacute rejection did not occur had very little or no dectable C4, factor B, properdin, C3, C5b, and membrane attack complex (Fig. 5) .
The basis for the hyperacute rejection of two xenografts in cynomolgus monkeys treated with human IgG was examined. There was no difference in the titers of xenoreactive antibodies or in graft preservation time between the monkeys in which hyperacute rejection occurred and the monkeys and baboons in which it was prevented. Levels of IgG, C4, properdin, and factor B in serum before transplantation were similar in both groups. The hyperacutely rejected xenografts had prominent deposits of properdin, C3, and membrane attack complex (Fig. 6 ), but very little or no C4 (as shown in Fig. 5) . Furthermore, the levels of factor B and properdin in the serum of these animals decreased very rapidly after perfusion of the grafts. These results suggested that complement had been activated via the alternative pathway, and these results are consistent with the possibility that Ig may not regulate this pathway to the same content as the classical pathway.
Effect ofIgG and xenotransplantation on serum complement activity. Administration of IgG before transplantation resulted in a 16-54% decrease in C4 titers. After xenotransplantation, the C4 titer fell rapidly, usually reaching a nadir 30-60 min after transplantation (Fig. 7) . This decrease in C4 was of a magnitude similar to that observed in unmanipulated cynomolgus monkeys after porcine cardiac xenotransplantation (32) . The rapid consumption of C4 after xenotransplantation suggests that the administration of Ig did not prevent the activation of the classical complement pathway but diverted the active complexes away from the graft.
Effect of administration of IgG and xenotransplantation on xenoreactive IgM and total Ig levels. Consistent with the results of in vitro studies, administration of IgG did not alter substantially the levels of xenoreactive IgM (Fig. 8) . As expected, levels of xenoreactive IgM decreased after reperfusion of the grafts, reaching a nadir 1/2-24 h after transplantation. The level of xenoreactive IgM in xenograft recipients began to increase between 1 and 4 d after transplantation and by posttransplant day 7 had increased appreciably, although the levels remained lower than the pretransplantation values as long as the xenograft continued to function.
After administration of IgG, the concentration of IgG in serum was 40-60 mg/ml and then decreased to the range of 20-40 mg/ml (Fig. 9) . IgM levels were decreased minimally 24 h after transplantation but then returned toward baseline levels. These results suggest that administration of IgG did not significantly decrease the synthesis of Ig. In the three cases (cyno 1 and both baboons), total IgM levels fell between 30 min and 24 h after transplantation, but by the fourth postoperative day, total IgM generally equaled or exceeded the pretransplant level. After rejection and removal of the xenograft, xenoreactive IgM levels rose to levels equal or greater to those observed before xenotransplantation. The titration curves then assumed a different shape, consistent with an alteration in the binding properties of xenoreactive IgM (not shown). Based on these results, it appears that administration of IgG did not significantly decrease the synthesis of Ig.
Discussion
Human IgG has been used as a therapeutic agent in the treatment of such autoimmune diseases as idiopathic thrombocytopenic purpura, Kawasaki disease, and myasthena gravis. The therapeutic effects of IgG have been attributed to various mechanisms including the blocking of Fc receptors and antiidiotype inhibition of pathogenic Igs (40, 41) . Ig may also regulate the complement cascade by preventing the binding of activated complement to antibody-coated targets (7, 8) . Here we report that IgG administered to a xenograft recipient prevents hyperacute rejection, and we present evidence that it is through the regulation of complement that rejection is averted. The studies reported here are the first in higher primates to demonstrate this mechanism.
Our investigations used a severe model in which the binding of xenoreactive natural antibodies, predominately IgM, to the graft endothelium activates complement via the classical pathway (11, 13, 18) . Complement activation in this model causes a dramatic loss of endothelial integrity and thrombosis leading rapidly to loss of graft function and destruction of organ. The mechanism by which IgG protects against complement-medi- ated injury in this model appears to involve prevention of complement deposition rather than inhibition of IgM binding. This mechanism differs from the mechanism proposed by Glotz and associates for the beneficial effects of gamma globulin on the outcome of allografts in presensitized subjects (43) . In the allograft recipients, IgG was thought to decrease circulating HLA-specific alloantibodies by idiotype interaction (43). Our results suggest that the complement regulatory effects of gamma globulin might confer additional protection in this setting.
IgG may inhibit complement deposition through one or more of several mechanisms. First, any aggregates present in the IgG preparations might cause the consumption of complement. This mechanism is unlikely to account for our observations because the preparations of gamma globulin used are > 98% IgG and based on sucrose density gradient ultracentrifugation and gel filtration they are free of aggregates. Nor do the IgG preparations consume complement when administered to humans (7) . However, the human IgG might well have formed A-1= ONL Figure 6 . Immunopathology of hyperacute rejection of a porcine cardiac xenograft in a cynomolgus monkey treated with purified human IgG. (A) properdin; (B) C5b; (C) membrane attack complex.
small amounts of complexes with the Ig of the nonhuman primates leading to a modest decrease in C4. However, the very rapid decline in C4 levels after transplantation consistent with our observations in unmanipulated primates ( 13 ) (32) prolong the survival of discordant xenografts for up to 5 d. While it is possible that gamma globulin has superior effects against complement, the greater prolongation of xenograft survival in our experiments may well reflect other therapeutic properties of IgG. Another advantage of IgG over other complement inhibitors may be that IgG selectively inhibits the classical pathway allowing the alternative pathway to function in host defense.
In the xenografts surviving more than 7 d, graft failure was associated with prominent evidence of thrombosis and patchy neutrophil infiltration, suggesting occurrence of acute vascular xenograft rejection (42) . This type of rejection is poorly under-30000- stood but may involve endothelial cell activation resulting in alteration in the coagulant and inflammatory properties of the endothelium (17, 42, 47) .
The hyperacute rejection of two porcine-to-cynomolgus monkey grafts due to activation of the alternative pathway complement is in contrast to the preponderance of our experience in pig-to-primate xenograft models (11, 46) and to our experience with perfusion of porcine organs by humans (48) . The mechanism of alternative pathway activation in these cases is not understood but several possibilities are worth consideration. First, the human IgG may have rendered the porcine endothelial surface capable of activating the alternative pathway (3, 49) or on binding to the graft it may have provided an C3b ligand resistant to inhibition by factors H and I (5). Second, it is possible that components expressed by some pigs but not others facilitate activation of the alternative pathway of primates (32) . Regardless of the mechanism, it would seem that IgG controls the alternative pathway less effectively than the classical pathway.
The studies reported here support earlier suggestions that IgG is not important in the pathogenesis of hyperacute xenograft rejection in porcine-to-primate xenotransplantation (11, 13) . Since the IgG preparations used consist almost entirely of functionally active IgG, its administration should enhance whatever pathogenetic mechanisms are initiated by that isotype of 1g. Yet, both in vitro and in vivo, purified IgG protected against complement-mediated injury and showed no evidence of provoking other detrimental changes.
